1. Updates in Preventing Skeletal-Related Events in Multiple Myeloma

2. Please note, this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Multiple Myeloma and Bone Disease

4. Diagnosing Bone Disease

5. Impact of Bone Disease

6. Pathophysiology of Bone Disease in MM

7. Bone-Modifying Agents

8. Myeloma IX Trial Study Design

9. Myeloma IX Trial Impact of ZA on Survival

10. Myeloma IX Trial Impact of ZA on SREs

11. Non-Inferiority Study of Denosumab vs ZA Study Design

12. Non-Inferiority Study of Denosumab vs ZA SREs and PFS

13. Key Treatment-Emergent Adverse Events

14. Reversibility of Bone Modifying Agents

15. ASCO and NCCN Guidelines for Treatment With BMAs

16. Treatment Duration With Bisphosphonates

17. Treatment Duration With Bisphosphonates (cont)

18. Managing AEs Induced by BMAs Expert Opinion

19. Key Takeaways

20. Abbreviations

21. Abbreviations (cont)

22. Abbreviations (cont)